Today, Amgen shared its 2026 first quarter earnings report. Amgen’s employees are united by our mission to serve patients. We harness the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller, and longer.
"Our first quarter results demonstrate the strength of our business, with 16 brands achieving double-digit growth, enabling us to grow through expected patent expirations and increased competition. With a new wave of molecules progressing in Phase 3 clinical development, we're confident in our ability to deliver attractive long-term growth," said Robert A. Bradway, chairman and chief executive officer.
The infographic below provides more highlights about the company’s 2026 first quarter results.
Additional details can be found in the earnings press release. Please see forward-looking statements.
A webcast of the earnings call can be found on Amgen’s Investors page.
